ライフサイエンスコーパス: rotavirus gastroenteritis

1 ssociation of secretor status against severe rotavirus gastroenteritis.

2 cted (98% [95% CI, 84%-100%]) against severe rotavirus gastroenteritis.

3 Serum Institute of India) to prevent severe rotavirus gastroenteritis.

4 and broadly heterologous protection against rotavirus gastroenteritis.

5 ody titers correlate with protection against rotavirus gastroenteritis.

6 de the broadest degree of protection against rotavirus gastroenteritis.

7 al stools, and 344 (19.8%) children ever had rotavirus gastroenteritis.

8 accine program will avert 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpatient admissions,

9 bservation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus

10 n of only G2 strains in these 3 outbreaks of rotavirus gastroenteritis among adults is similar to res

11 ine, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in Niger.

12 ldren may translate to an enhanced burden of rotavirus gastroenteritis among this group.

13 erse events and is efficacious in preventing rotavirus gastroenteritis and associated healthcare enco

14 otavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus il

15 ompetent children who required treatment for rotavirus gastroenteritis at a large pediatric hospital

16 he field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain

17 pidemiologic association among children with rotavirus gastroenteritis compared with healthy control

18 needed to be immunised to prevent one severe rotavirus gastroenteritis episode was 55 (95% CI 37-97).

19 nd approximatel 100% efficacy against severe rotavirus gastroenteritis for the first rotavirus infect

20 The primary outcome was incidence of severe rotavirus gastroenteritis (>/=11 on the Vesikari scale).

21 Children recovering from rotavirus gastroenteritis have increased gamma interfero

22 1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency

23 ore doses of rotavirus vaccine in preventing rotavirus gastroenteritis hospitalizations ranged from 8

24 real-time PCR to establish the diagnosis of rotavirus gastroenteritis in a high-disease-burden popul

25 as evaluated by comparing the frequencies of rotavirus gastroenteritis in an intention-to-treat analy

26 The prominent decline in severe rotavirus gastroenteritis in areas with mature rotavirus

27 s vaccines have reduced the health burden of rotavirus gastroenteritis in both developed and developi

28 the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developi

29 Outbreaks of rotavirus gastroenteritis in elderly adults are reported

30 cted toward development of a vaccine against rotavirus gastroenteritis in infants.

31 nt human-bovine rotavirus vaccine for severe rotavirus gastroenteritis in low-resource urban and rura

32 infection on the presentation and outcome of rotavirus gastroenteritis in Malawian children.

33 ssess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduct

34 cacy analysis, there were 31 cases of severe rotavirus gastroenteritis in the vaccine group and 87 ca

35 icantly protected against medically attended rotavirus gastroenteritis in this real-world assessment.

36 However, the incidence of rotavirus gastroenteritis is predicted to remain low des

37 Each year, rotavirus gastroenteritis is responsible for about 37% o

38 tified with clinical or laboratory-confirmed rotavirus gastroenteritis (median age, 84 years) and 11

39 cantly lower rates of hospitalization with a rotavirus gastroenteritis or unspecified-gastroenteritis

40 The incidence of severe rotavirus gastroenteritis per 100 person-years was 1.5 i

41 Rotavirus gastroenteritis rates among rotavirus vaccines

42 emonstrated 68.8%-76.6% efficacy against any rotavirus gastroenteritis, regardless of severity, and a

43 ce interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a

44 study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa,

45 ength of naturally acquired immunity against rotavirus gastroenteritis (RVGE), mirroring vaccine unde

46 rts of children with acute or fatal cases of rotavirus gastroenteritis testing positive for rotavirus

47 Two new vaccines against severe rotavirus gastroenteritis that have high efficacy in mid

48 ochester, NY, with sequence-confirmed G8P[4] rotavirus gastroenteritis-the first U.S. detection of th

49 the morbidity and mortality associated with rotavirus gastroenteritis through vaccination is support

50 first episode of laboratory-confirmed severe rotavirus gastroenteritis (Vesikari score, >/=11) beginn

51 acebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53.6% (95% CI 35.0-66.9; p

52 The median age of children with rotavirus gastroenteritis was 7.8 months, compared with

53 Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals i

54 Severe rotavirus gastroenteritis was virtually absent among US

55 71 events of severe rotavirus gastroenteritis were reported in 4752 person-y

56 io of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negati